<div id="readability-page-1"><p>In a report released today, Anna Lizzul from Bank of America Securities reiterated a Buy rating on Kimberly Clark, with a price target of <span id="expert-recommendation-target">$120.00</span>.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Anna Lizzul has given his Buy rating due to a combination of factors tied to Kimberly-Clark’s proposed acquisition of Kenvue and the stock’s recent pullback. He views KMB as a strategic acquirer of Kenvue’s assets, emphasizing that the categories are complementary and that the purchase price and EBITDA multiple look attractive relative to where Kenvue traded before Tylenol-related headline pressure.</p> <p>He also highlights the sizable potential for value creation from the combined company’s scale, projected revenue and EBITDA base, and planned cost and revenue synergies, especially if sector valuation multiples recover after a difficult start to 2026. In addition, he notes that some of Kenvue’s higher-growth, higher-margin brands—particularly in self care—could enhance KMB’s portfolio over time, while perceived legal overhangs on Tylenol appear to be easing, supporting his unchanged $120 price target and Buy stance.</p> <p>Lizzul covers the Consumer Defensive sector, focusing on stocks such as Clorox, Kimberly Clark, and Coty. According to TipRanks, Lizzul has an average return of <span>-2.5%</span> and a 38.79% success rate on recommended stocks. </p> <p>In another report released on April 29, RBC Capital also reiterated a Buy rating on the stock with a $162.00 price target.</p></div>

<p>Anna Lizzul from Bank of America Securities has reiterated a Buy rating on Kimberly-Clark with a price target of $120. The rating is supported by the strategic acquisition of Kenvue, which is expected to create value through synergies and enhance Kimberly-Clark's portfolio. Lizzul notes the attractive purchase price and potential for revenue growth, especially as legal concerns regarding Tylenol ease. RBC Capital also maintains a Buy rating with a higher price target of $162.</p>

Tip Ranks

Kimberly Clark

Kenvue

Bank of America

Clorox

Coty

ROYAL BANK OF CANADA

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Buy Rating Reiterated on Kimberly-Clark as Strategic Kenvue Deal and Synergy Upside Support Unchanged $120 Price Target